An increased high-density lipoprotein cholesterol/ apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality

Heart

Volumn 101, Issue 7, 2015, Pages 553-558

  Sung, Ki Chul ^a,d   Ryu, Seungho ^a   Wild, Sarah H ^b   Byrne, Christopher D ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; BLOOD; CAUSE OF DEATH; MIDDLE AGED; MORTALITY; RISK FACTOR;

ADULT; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84927646051     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306784     Document Type: Article

References (28)

1. Nicholls SJ, Puri R. Is it time for HDL to change its tune? Circulation 2013;128:1175-6.
2. Gielen S, Landmesser U. The Year in Cardiology 2013: cardiovascular disease prevention. Eur Heart J 2014;35:307-12.
3. Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine 2011;365:2255-67.
4. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
5. Sung KC, Wild SH, Byrne CD. Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis. Atherosclerosis 2013;231:181-6.
6. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.
7. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011;22:176-85.
8. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011;17:594-603.
9. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010;21:229-38.
10. Mackey RH, Greenland P, Goff DC Jr, et al High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60:508-16.
11. Brewer HB Jr. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011;96:1246-57.
12. Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res 2014; 55:168-79.
13. Duong PT, Collins HL, Nickel M, et al. Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I. J Lipid Res 2006;47:832-43.
14. Liu L, Bortnick AE, Nickel M, et al. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol Chem 2003;278:42976-84.
15. Sorci-Thomas MG, Owen JS, Fulp B, et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res 2012;53:1890-909.
16. Lund-Katz S, Lyssenko NN, Nickel M, et al. Mechanisms responsible for the compositional heterogeneity of nascent high density lipoprotein. J Biol Chem 2013;288:23150-60.
17. Lyssenko NN, Nickel M, Tang C, et al. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability. FASEB J 2013;27:2880-92.
18. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011;121:4138-49.
19. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, et al . Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012;11:195-206.
20. Murphy AJ, Hoang A, Aprico A, et al . Anti-inflammatory functions of apolipoprotein A-I and high-density lipoprotein are preserved in trimeric apolipoprotein A-I. J Pharmacol Exp Ther 2013;344:41-9.
21. Ohnsorg PM, Mary JL, Rohrer L, et al. Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells. Biochim Biophys Acta 2011;1811:1115-23.
22. Luc G, Bard JM, Ferrieres J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002;22:1155-61.
23. Sharrett AR, Ballantyne CM, Coady SA, et al . Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13.
24. Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 2013;128:1504-12.
25. Verma N, Figueredo VM. HDL Cholesterol: All Hope Is Not Lost After the Torcetrapib Setback- Emerging Therapeutic Strategies on the Horizon. Am J Ther 2014;21:222-32.
26. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013;128:1189-97.
27. Chiva-Blanch G, Urpi-Sarda M, Ros E, et al. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin Nutr 2013;32:200-6.
28. Remaley AT. Apolipoprotein A-II: still second fi ddle in high-density lipoprotein metabolism? Arterioscler Thromb Vasc Biol 2013;33:166-7.